Galectin Therapeutics Inc. (GALT) Financial Statements (2026 and earlier)

Company Profile

Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD
NORCROSS, GA 30071
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments17,720,00011,525,00013,771,0007,431,00015,120,00027,060,000
Cash and cash equivalent17,720,00011,525,00013,771,0007,431,00015,120,00027,060,000
Other undisclosed current assets1,716,0001,204,0001,656,0001,854,0002,132,0001,606,000
Total current assets:19,436,00012,729,00015,427,0009,285,00017,252,00028,666,000
Noncurrent Assets
Other noncurrent assets96,000136,000175,000243,000243,000306,000
Total noncurrent assets:96,000136,000175,000243,000243,000306,000
TOTAL ASSETS:19,532,00012,865,00015,602,0009,528,00017,495,00028,972,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,967,00010,428,00010,711,00013,429,00013,860,00014,381,000
Accounts payable3,245,0005,390,0005,865,0006,534,0005,656,0002,795,000
Accrued liabilities4,722,0005,038,0004,846,0006,895,0008,204,00011,586,000
Derivative instruments and hedges, liabilities  3,742,000 305,000369,000359,000
Other undisclosed current liabilities 63,000122,275,00063,00097,106,00021,180,00010,518,000
Total current liabilities:8,030,000136,445,00010,774,000110,840,00035,409,00025,258,000
Noncurrent Liabilities
Liabilities, other than long-term debt3,962,000 1,537,000136,00047,0002,159,000
Derivative instruments and hedges, liabilities3,962,000 1,537,000136,00047,0002,159,000
Other undisclosed noncurrent liabilities133,735,000 120,458,00010,813,00085,109,00094,036,000
Total noncurrent liabilities:137,697,000 121,995,00010,949,00085,156,00096,195,000
Total liabilities:145,727,000136,445,000132,769,000121,789,000120,565,000121,453,000
Temporary equity, including noncontrolling interest1,723,0001,723,0001,723,0001,723,0001,723,0001,723,000
Equity
Equity, attributable to parent(127,918,000)(125,303,000)(118,890,000)(113,984,000)(104,793,000)(94,204,000)
Preferred stock490,000490,000490,000500,000500,000500,000
Common stock65,00064,00063,00063,00062,00062,000
Additional paid in capital304,073,000301,127,000299,318,000296,630,000296,217,000294,776,000
Accumulated deficit(432,546,000)(426,984,000)(418,761,000)(411,177,000)(401,572,000)(389,542,000)
Total equity:(127,918,000)(125,303,000)(118,890,000)(113,984,000)(104,793,000)(94,204,000)
TOTAL LIABILITIES AND EQUITY:19,532,00012,865,00015,602,0009,528,00017,495,00028,972,000

Income Statement (P&L) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Operating expenses(3,365,000)(4,198,000)(4,625,000)(7,897,000)(12,428,000)(9,066,000)
Operating loss:(3,365,000)(4,198,000)(4,625,000)(7,897,000)(12,428,000)(9,066,000)
Nonoperating income (expense)(2,135,000)(3,986,000)(2,896,000)(1,734,000)461,000(2,154,000)
Investment income, nonoperating(196,000)(2,166,000)(1,070,000)10,0002,186,000(660,000)
Interest and debt expense(1,939,000)(1,820,000)(1,826,000)(1,744,000)(1,725,000)(1,494,000)
Net loss:(7,439,000)(10,004,000)(9,347,000)(11,375,000)(13,692,000)(12,714,000)
Other undisclosed net income attributable to parent1,939,0001,820,0001,826,0001,744,0001,725,0001,494,000
Net loss attributable to parent:(5,500,000)(8,184,000)(7,521,000)(9,631,000)(11,967,000)(11,220,000)
Preferred stock dividends and other adjustments(62,000)(39,000)(63,000)26,000(63,000)(18,000)
Net loss available to common stockholders, diluted:(5,562,000)(8,223,000)(7,584,000)(9,605,000)(12,030,000)(11,238,000)

Comprehensive Income (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net loss:(7,439,000)(10,004,000)(9,347,000)(11,375,000)(13,692,000)(12,714,000)
Comprehensive loss, net of tax, attributable to parent:(7,439,000)(10,004,000)(9,347,000)(11,375,000)(13,692,000)(12,714,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: